Biocytogen Pharmaceuticals (Beijing) Co Ltd is a China-based company primarily engaged in the provision of innovative animal models and pre-clinical pharmaceutical research and development services based on its independently developed gene-editing technology. The Company utilizes its self-developed RenMice fully human antibody and T-cell receptor (TCR) mouse platform for large-scale drug discovery and development targeting potential drug targets in the human body. The Company’s main businesses include the sale of innovative animal models, pre-clinical pharmacology and efficacy evaluation services, and antibody development. The Company is also engaged in the provision of gene-editing services. The Company operates its businesses in the domestic market and overseas markets.